相关实验视频

Updated: May 3, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

膜胆固醇依赖的双重VEGFR2 / FGFR1抑制由金赛诺化物Rg3克服gefitinib在NSCLC的耐药性

Min Jiang¹, Chao Hong², Wenkui Zou¹

¹School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

Phytomedicine : international journal of phytotherapy and phytopharmacology

|November 5, 2025

概括

银化物Rg3与gefitinib结合,通过向胆固醇-脂质互动,克服非小细胞肺癌 (NSCLC) 中的耐药性. 这种新的策略恢复了EGFR-TKI对罕见突变的疗效,提供了一个有前途的临床方法.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

对表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 的耐药性是非小细胞肺癌 (NSCLC) 治疗的一个主要挑战.
罕见的向突变 (<5%的发病率) 显著导致耐药性,由于其复杂性,可用的向疗法有限.

研究的目的:

为NSCLC开发一种新的治疗策略,同时抑制多个抗性驱动因素.
通过克服单蛋白抑制剂的局限性来增强对EGFR-TKI的药物复敏性.

主要方法:

已建立的耐替尼布NSCLC细胞模型与罕见的同活性EGFR独立膜蛋白.
开发了一种针对脂质胆固醇的策略,使用人参化物破坏的完整性.
在体外和体内评估了人参酸Rg3和gefitinib的协同效应,探索了Rg3的作用机制.

主要成果:

在NSCLC模型中,合并使用人参化物Rg3和gefitinib协同恢复了抗瘤疗效.
通过与脂质胆固醇结合,Rg3破坏了抵抗相关受体氨酸激酶 (FGFR1,VEGFR2) 的膜定,加速了它们的降解.
结构分析确定了关键的金氏化物部分 (C3,C6,C20),对于胆固醇结合和抵抗逆转至关重要.

结论:

一种新的以膜为中心的方法,利用胆固醇-脂质相互作用的药理学破坏,可以克服NSCLC中的多驱动器抵抗.
金色化物Rg3在NSCLC患者的共存抵抗机制的广泛抑制方面呈现出一个有前途的临床策略.
这项研究为NSCLC耐药性机制提供了新的见解,并为改善患者治疗结果提供了潜在的途径.

关键词:

耐吉提尼布耐药性耐吉提尼布耐药性吉尼斯诺化物是什么脂质漂浮在胆固醇上胆固醇这是一种罕见的共变异.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...